Secondary HyperparathyroidismTreatment Market: Regional Insights
On the basis of region, theglobal SecondaryHyperparathyroidism Treatment Market by Coherent Market Insights issegmented into North America, Latin America, Europe, Asia Pacific, Middle East,and Africa. North America holds a dominant position in the global secondaryhyperparathyroidism treatment market, owing to increasing research anddevelopment of novel therapies and potential drugs for secondaryhyperparathyroidism as well as high prevalence of chronic kidney disease.According to the Centers of Disease Control & Prevention (CDC), in 2014,118,000 people in the U.S. started treatment for ESRD, and 662,000 were livingon chronic dialysis. Furthermore, Europe is expected to be the second-largestcontributor in the secondary hyperparathyroidism treatment market, in terms ofrevenue and is expected to gain significant traction in the near future. Thisis owing to launch of new drugs and therapies, to combat secondaryhyperparathyroidism as well as presence of significant population sufferingfrom the disease in this region. For instance, in December 2016, Amgen’s drugetecalcetide (Parsabiv), received marketing approval in Europe by the European Commissionfor treatment of secondary hyperparathyroidism in adult patients with chronickidney diseases. Furthermore, Asia Pacific is expected to be the fastestgrowing region, owing to regional companies conducting clinical trials forlaunch of new drugs. For instance, Kyowa Hakko Kirin China Pharmaceutical Co.,Ltd is under Phase 4 clinical trial to determine the safety and efficacy of itsnew lead compound Cinacalet for treatment of patients suffering with mild tomoderate SHPT and expected to be launched in the market by April 2019.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1570
Secondary hyperparathyroidism(SHPT) refers to one of the serious, common, and progressive complicationassociated with Chronic Kidney Disease (CKD) that is mainly characterized byhigh levels of parathyroid hormone, mineral metabolism abnormalities, and parathyroidgland hyperplasia. Failing kidneys are unable to convert Vitamin A to itsactive form as they do not adequately excrete phosphate resulting intoformation of insoluble calcium phosphate by the body thus, leading to secondaryhyperparathyroidism. The common signs and symptoms of the disease includes boneand joint pain as well as limb deformities. The disturbances caused in thesecondary hyperparathyroidism patients may lead to poor quality of life andshort life expectancy. Treatment for SHPT involves surgical operation orconsumption of prescribed drugs that helps to maintain the level of parathyroidhormone, calcium, and phosphorous within the accepted targeted areas. Accordingto the U.S. Food & Drug Administration (FDA) 2012, Secondary hyperparathyroidismis a serious chronic condition that affects a high percentage of patientsreceiving kidney dialysis. In case of prognosis, if the SHPT is left untreated,the disease progresses to tertiary hyperparathyroidism and is then associatedwith hypercalcemia. According to the National Institute of Diabetes &Digestive & Kidney Diseases, the two prime reasons resulting in chronickidney disease are diabetes and high blood pressure. Patients suffering fromCKD, due to one of the reasons, if remain undetected can progress toirreversible kidney failure.
Secondary Hyperparathyroidism TreatmentMarket: Market Dynamics
Rising incidence of chronickidney diseases is one of the major factors responsible for growth of theglobal secondary hyperparathyroidism treatment market. According to Centers ofDisease Control & Prevention (CDC) 2017, 30 million people or 15% of theU.S. adults are estimated to have chronic kidney disease, out of which 48%suffer severely with reduced kidney function, however, are not aware of havinga CKD.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/secondary-hyperparathyroidism-treatment-market-1570
Moreover, according to theNational Kidney Foundation 2016, 10% of the population across the world areaffected with chronic kidney diseases. Additionally, extensive research in thefield of nephrology to come up with new drugs and therapies for treatment ofsecondary hyperparathyroidism is responsible for fueling growth of the market.For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinicaltrials to evaluate the safety and efficacy of this medication in reducing the levelof secondary hyperparathyroidism in pediatric patients with chronic kidneydiseases at stage 3 and 4. The drug is expected to complete its study inDecember 2017, and be commercially available in market. However, side effectsusually associated with secondary hyperparathyroidism treatment such as musclespasm, diarrhea, and vomiting may cause hindrance to growth of the market.
Secondary HyperparathyroidismTreatment Market: Competitive Analysis
Key players operating in theglobal secondary hyperparathyroidism treatment market include AbbVie, Inc.,Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG,Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc.,Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing oninnovation and new product development, to maintain their position in themarket and enhance their share. For instance, in June 2016, OPKO Healthintroduced Rayaldee (calcifediol) for the treatment of SHPT in adults withstage 3 or 4 of chronic kidney disease.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1570
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offering action-readysyndicated research reports, custom market analysis, consulting services, andcompetitive analysis through various recommendations related to emerging markettrends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
